We have investigated the SAR of a series of pyrimidinone-containing Cdc7 kinase inhibitors. A wide range of amine substitutions give potent compounds with activities (K-i) less than 1 nM. Kinase selectivity is reasonable and cytotoxicity corresponds to inhibition of MCM2 phosphorylation. (c) 2012 Elsevier Ltd. All rights reserved.
We have investigated the SAR of a series of pyrimidinone-containing Cdc7 kinase inhibitors. A wide range of amine substitutions give potent compounds with activities (K-i) less than 1 nM. Kinase selectivity is reasonable and cytotoxicity corresponds to inhibition of MCM2 phosphorylation. (c) 2012 Elsevier Ltd. All rights reserved.
Pyrimidinone compounds useful as kinase inhibitors
申请人:Hasegawa Masaichi
公开号:US20070117818A1
公开(公告)日:2007-05-24
This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.
PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:EP1713793A2
公开(公告)日:2006-10-25
EP1713793A4
申请人:——
公开号:EP1713793A4
公开(公告)日:2009-09-02
[EN] NOVEL CHEMICAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES CHIMIQUES
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2005076854A2
公开(公告)日:2005-08-25
This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.